Jetzt noch länger handeln: 7:30 - 23:00
Mit uns direkt oder auf gettex.
Über deinen Broker oder Deine Bank.

L&G Pharma Breakthrough UCITS ETF USD Acc

WKNA2H9XR
AssetklasseAktien
10,712+0,05
+0,45%
30.09.2025 20:47
10,712+0,05
+0,45%
30.09.2025 20:47
Keine Daten verfügbar
Eröffnung
10,52
Hoch
10,76
Tief
10,52
Umsatz
10,76
The Fund is a passively managed exchange traded Fund that aims to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the Index), subject to the deduction of the ongoing charges and other costs associated with operating the Fund. The index is comprised of bio-technology companies which are publically traded on various stock exchanges around the world that are actively engaged in the research, development and manufacture of orphan drugs. An orphan drug is a pharmaceutical product that has been developed specifically to treat rare diseases or disorders.
Emittent
LGIM Managers (Europe) Ltd
Benchmark
Solactive Pharma Breakthrough Value NR USD
Fondsgröße in Mio.
16,748
Gesamtkostenquote (TER)
0,49 %
Tracking Difference
2,889
Replikation
Physisch
Fondswährung
USD
Domizil
IE
Fondsauflage
-
Ausschüttung
Thesaurierend
Ausschüttungsintervall
-
NAV
12,4623
NAV Datum
29.9.2025